1,056 results on '"Freedland, Stephen J."'
Search Results
2. EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL).
3. EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL).
4. A qualitative exploration of perceptions of the value of wearable activity monitors among prostate cancer survivors undergoing androgen deprivation therapy.
5. Race and association between ADT and adverse events.
6. Impact of mental health illness (MHI) prior to prostate cancer (PC) diagnosis (Dx) on treatment (Tx) received and PC outcomes.
7. Metabolic Response to Androgen Deprivation Therapy of Prostate Cancer
8. PD05-08 ADDRESSING RACIAL DISPARITIES IN PROSTATE CANCER PATHOLOGY PREDICTION MODELS: EXTERNAL VALIDATION AND COMPARISON OF FOUR MODELS OF PATHOLOGICAL OUTCOME PREDICTION BEFORE RADICAL PROSTATECTOMY
9. PD03-05 DOES INSULIN RESISTANCE CREATE A BIGGER PROSTATE? RESULTS FROM THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) TRIAL
10. PD61-01 SPECIALTY BIAS IN REPORTING OF ADVANTAGES AND DISADVANTAGES OF TREATMENT OPTIONS IN CONSULTATIONS FOR EARLY STAGE PROSTATE CANCER
11. MP12-13 WHAT WOULD YOU DO IF IT WERE YOU, DOC?: PATIENT AND PHYSICIAN PERSPECTIVES ON WHY PROSTATE CANCER PATIENTS SEEK “PERSONAL ADVICE” FROM PROVIDERS AND HOW PHYSICIANS RESPOND
12. PD48-05 USE OF BLUE LIGHT CYSTOSCOPY AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS AND OUTCOMES IN AN EQUAL ACCESS SETTING: A PROPENSITY SCORED MATCHED ANALYSIS
13. MP24-01 INTEGRATING NATURAL LANGUAGE PROCESSING WITH CHATGPT TO IMPROVE QUALITY OF ARTIFICIAL INTELLIGENCE SUMMARIES OF PROSTATE CANCER CONSULTATIONS
14. PD62-05 PATIENT PERCEPTIONS OF STANDARDIZED RISK LANGUAGE USED IN AMERICAN COLLEGE OF RADIOLOGY PROSTATE MRI PIRADS SCORES
15. MP34-01 BASELINE PROSTATE-SPECIFIC ANTIGEN SCREENING VALUES IN TRANSGENDER WOMEN ON GENDER-AFFIRMING HORMONE THERAPY: A NATIONAL COHORT STUDY
16. MP60-02 REAL WORLD TREATMENT SEQUENCE AND SURVIVAL IN LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER AND POSTPROGRESSION DISEASE STATES
17. PD29-01 DOES INSULIN RESISTANCE PREDICT AGGRESSIVE PROSTATE CANCER? RESULTS FROM THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER (REDUCE) TRIAL
18. PD01-06 PROSTATE-SPECIFIC ANTIGEN DYNAMICS FROM THE PHASE 3 EMBARK TRIAL: A POST HOC ANALYSIS
19. Applications of wearable activity monitors for prostate cancer survivors: A systematic scoping review
20. Addressing racial disparities in prostate cancer pathology prediction models: external validation and comparison of four models of pathological outcome prediction before radical prostatectomy in the multiethnic SEARCH cohort
21. Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer
22. Dietary Fiber Intake and Risk of Advanced and Aggressive Forms of Prostate Cancer: A Pooled Analysis of 15 Prospective Cohort Studies
23. Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
24. Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors
25. COMPARING WHITE LIGHT VERSUS BLUE LIGHT CYSTOSCOPY RECURRENCE OUTCOMES AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS IN AN EQUAL ACCESS SETTING: A PROPENSITY SCORED MATCHED ANALYSIS
26. Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era
27. LONGITUDINAL CHANGES IN PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH HIGH-RISK BIOCHEMICALLY RECURRENT (BCR) NONMETASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) FROM THE EMBARK STUDY
28. Use of Persuasive Language in Communication of Risk during Prostate Cancer Treatment Consultations
29. Filamin A Is a Prognostic Serum Biomarker for Differentiating Benign Prostatic Hyperplasia from Prostate Cancer in Caucasian and African American Men
30. Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH
31. Adherence to the World Cancer Research Fund lifestyle recommendations and incidence of prostate cancer in UK Biobank
32. Correction: Application of next-generation imaging in biochemically recurrent prostate cancer
33. Adverse events and costs among non-metastatic castration-resistant prostate cancer patients
34. Potential miscommunication of risk in American College of Radiology Prostate Imaging and Data System (PIRADS) scores
35. A Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group
36. 27-hydroxycholesterol and DNA damage repair: implication in prostate cancer
37. The effects of glycemic index on prostate cancer progression in a xenograft mouse model
38. The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence
39. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer
40. A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients
41. Genetic and biological drivers of prostate cancer disparities in Black men
42. Reply by Authors
43. Bladder Instillation Patterns in a Cohort of Women With Interstitial Cystitis/Bladder Pain Syndrome
44. Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?
45. Serum Testosterone and Dihydrotestosterone and Incidence and Progression of Lower Urinary Tract Symptoms: Results From the REDUCE Study
46. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
47. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population
48. Are higher follicle-stimulating hormone levels before androgen deprivation therapy for prostate cancer associated with oncological and cardiac outcomes and overall survival?—a population-level analysis
49. ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer
50. Relative search popularity of five advanced prostate cancer medications using Google Trends
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.